Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combinatory ImmunoTherapy-2 (Com-IT-2)
2023-510089-28-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, pembrolizumab, nivolumab and cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Acute toxicity (0-3 months) and Subacute toxicity (3-6 months). Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-510089-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510089-28-00.